RetinalGenix Technologies (RTGN) Total Non-Current Liabilities (2022 - 2026)
RetinalGenix Technologies (RTGN) posted Total Non-Current Liabilities of $1.7 million for Q1 2026, down 5.53% sequentially from $1.8 million in Q4 2025, and up 47.71% YoY from $1.2 million in Q1 2025.
RetinalGenix Technologies (RTGN) Total Non-Current Liabilities (2022 - 2026) Analysis & Trends
RetinalGenix Technologies has reported Total Non-Current Liabilities for 5 years, with the latest figure at $1.7 million in Q1 2026.
- Quarterly Total Non-Current Liabilities rose 47.71% year-over-year to $1.7 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $1.7 million (up 47.71% YoY) and the FY2025 annual result came in at $1.8 million, up 81.67% from the prior year.
- Total Non-Current Liabilities retreated to $1.7 million in Q1 2026 per RTGN's latest filing, from $1.8 million in the prior quarter.
- Over five years, Total Non-Current Liabilities peaked at $1.8 million in Q4 2025 and troughed at $459804.0 in Q2 2022.
- A 5-year average of $1.3 million and a median of $1.3 million in 2023 frame the typical range for Total Non-Current Liabilities.
- The sharpest annual moves came in 2023 and 2025: Total Non-Current Liabilities surged 110.05% in 2023, then slipped 14.76% in 2025.
- Over 5 years, Total Non-Current Liabilities stood at $959815.0 in 2022, then fell by 1.2% to $948279.0 in 2023, then rose by 6.48% to $1.0 million in 2024, then jumped by 81.67% to $1.8 million in 2025, then slipped by 5.53% to $1.7 million in 2026.
- According to Business Quant data, Total Non-Current Liabilities over the past three periods registered $1.7 million, $1.8 million, and $1.6 million for Q1 2026, Q4 2025, and Q3 2025 respectively.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Total Non-Current Liabilities (Qtr) |
|---|---|---|---|---|---|
| 1 | Abbott Laboratories | 198.70 Bn | 193.10 Bn | 7.27 Bn | - |
| 2 | Stryker | 125.85 Bn | 122.37 Bn | 4.50 Bn | 21.28 Bn |
| 3 | Medtronic | 118.44 Bn | 109.22 Bn | 6.41 Bn | 40.90 Bn |
| 4 | Boston Scientific | 72.64 Bn | 72.10 Bn | 3.85 Bn | 42.74 Bn |
| 5 | Edwards Lifesciences | 51.94 Bn | 47.69 Bn | 1.35 Bn | 2.57 Bn |
| 6 | Dexcom | 34.48 Bn | 32.53 Bn | 830.00 Mn | 3.68 Bn |
| 7 | GE HealthCare Technologies | 33.60 Bn | 31.49 Bn | 2.18 Bn | 23.89 Bn |
| 8 | Koninklijke Philips | 26.30 Bn | 22.98 Bn | 4.55 Bn | 9.07 Bn |
| 9 | Steris | 23.00 Bn | 22.52 Bn | 684.20 Mn | 3.44 Bn |
| 10 | RetinalGenix Technologies | 75.02 Mn | 75.02 Mn | - | 1.73 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 1.73 Mn |
| Dec 31, 2025 | 1.83 Mn |
| Sep 30, 2025 | 1.64 Mn |
| Jun 30, 2025 | 1.44 Mn |
| Mar 31, 2025 | 1.17 Mn |
| Dec 31, 2024 | 1.01 Mn |
| Sep 30, 2024 | 1.47 Mn |
| Jun 30, 2024 | 1.35 Mn |
| Mar 31, 2024 | 1.38 Mn |
| Dec 31, 2023 | 948,279.00 |
| Sep 30, 2023 | 1.08 Mn |
| Jun 30, 2023 | 965,824.00 |
| Mar 31, 2023 | 1.31 Mn |
| Dec 31, 2022 | 959,815.00 |
| Jun 30, 2022 | 459,804.00 |